Patrick Kesteven

2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Molecular Analysis of Commensal Host-Microbial Relationships in the Intestine

Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation

2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease

Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation

Contribution of Neutrophils to Acute Lung Injury

Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism

Technology platforms for pharmacogenomic diagnostic assays

Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin®) in the prophylaxis of thromboembolic complications of abdominal oncological surgery

Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends

Pharmacology and Management of the Vitamin K Antagonists

A Prospective, Randomized Pilot Trial of Model-Based Warfarin Dose Initiation using CYP2C9 Genotype and Clinical Data

Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation

Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists

Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin

Natriuretic peptides and troponins in pulmonary embolism: a meta-analysis

Intracerebral haemorrhage

Evidence-Based Management of Anticoagulant Therapy

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention

Cytochrome P450 and the Individuality of Species

VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation

Ultrasound in the detection of venous thromboembolism

Association Between CYP2C9 Genetic Variants and Anticoagulation-Related Outcomes During Warfarin Therapy

Oral Anticoagulant Therapy

Assessing the cost-effectiveness of pharmacogenomics

Daily vitamin K supplementation improves anticoagulant stability

Guillain-Barré syndrome

Combined genetic profiles of components and regulators of the vitamin K-dependent γ-carboxylation system affect individual sensitivity to warfarin

Diabetic neuropathy and oxidative stress

Drug-Induced Hepatotoxicity

Emergency Hospitalizations for Adverse Drug Events in Older Americans

Incidence of Air Travel–Related Pulmonary Embolism at the Madrid-Barajas Airport

Transient receptor potential channels: targeting pain at the source

2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults

Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype

Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

Mechanisms of Actions of Inhaled Anesthetics

A Prospective Natural-History Study of Coronary Atherosclerosis

Prevention of VTE in Nonsurgical Patients

Heat Shock Protein A12B Protects Vascular Endothelial Cells Against Sepsis-Induced Acute Lung Injury in Mice

Oxidation of low-density lipoprotein in NIDDM: its relationship to fatty acid composition

Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9

Warfarin dosing and cytochrome P450 2C9 polymorphisms

Self-monitoring of oral anticoagulation: a systematic review and meta-analysis

Risks factors for highly unstable response to oral anticoagulation: a case‐control study

Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study

Potential Role of Pharmacogenomics in Reducing Adverse Drug Reactions

Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism

Premature peripheral vascular disease: clinical profile and abnormal lipid peroxidation

Travel and venous thrombosis

CYP2C9 Genotype-guided Warfarin Prescribing Enhances the Efficacy and Safety of Anticoagulation: A Prospective Randomized Controlled Study

Warfarin and its interactions with foods, herbs and other dietary supplements

Pharmacogenomics: Challenges and Opportunities

Warfarin Interactions With Substances Listed in Drug Information Compendia and in the FDA-Approved Label for Warfarin Sodium

Interaction of Warfarin With Drugs, Natural Substances, and Foods

Inheritance and Drug Response

Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin

Deep vein thrombosis and air travel: record linkage study

The Missing Diversity in Human Genetic Studies

Rescue Angioplasty or Repeat Fibrinolysis After Failed Fibrinolytic Therapy for ST-Segment Myocardial Infarction

Diabetes and Atherosclerosis

Common VKORC1 and GGCX polymorphisms associated with warfarin dose

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

Venous Thrombosis After Long-haul Flights

Prevention of Venous Thromboembolism

Identification and Functional Characterization of a New CYP2C9 Variant (CYP2C9*5) Expressed among African Americans

Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment

Interindividual variability in sensitivity to warfarin-Nature or nurture?

Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range

Effect of Study Setting on Anticoagulation Control

Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty

Several-fold increase in risk of overanticoagulation by CYP2C9 mutations

Pharmacogenetics of Warfarin Elimination and its Clinical Implications

Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention

Osteoarthritis year in review 2016: genetics, genomics and epigenetics

The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon

New anticoagulants: how to deal with treatment failure and bleeding complications

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

The Pharmacology and Management of the Vitamin K Antagonists

Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment

Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy

Influence of dietary vitamin K intake on subtherapeutic oral anticoagulant therapy

Does heart failure exacerbation increase response to warfarin?A critical review of the literature

Osteoarthritis

Influence of CYP2C9 genotype on warfarin dose requirements—a systematic review and meta-analysis

CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences

haplotype structure in European American warfarin patients and association with clinical outcomes

Prophylaxis of thromboembolism in general surgery: Comparison between standard heparin and fragmin

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans

Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: a retrospective analysis of case records

Frequency of venous thromboembolism in low to moderate risk long distance air travellers: the New Zealand Air Traveller's Thrombosis (NZATT) study

Neutrophil recruitment and function in health and inflammation

Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59‐7939) in Healthy Subjects

Pharmacogenetics and adverse drug reactions

Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population

Guidelines for the Early Management of Patients With Acute Ischemic Stroke

Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial

Venous thromboembolism in travellers: can we identify those at risk?

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

Delivery of Optimized Anticoagulant Therapy: Consensus Statement from the Anticoagulation Forum

Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss

ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic)

Nanozymes: Classification, Catalytic Mechanisms, Activity Regulation, and Applications

Influence of CYP2C9 and VKORC1 on Warfarin Dose, Anticoagulation Attainment and Maintenance Among European–Americans and African–Americans

A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity

Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon

Pharmacogenomics: Unlocking the Human Genome for Better Drug Therapy

Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment

Guillain-Barr� syndrome and chronic inflammatory demyelinating polyneuropathy: Immune mechanisms and update on current therapies

American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy

Guidelines for the Primary Prevention of Stroke

The influence of sequence variations in factor VII, γ-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement

Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients

Improved Oral Anticoagulation After a Dietary Vitamin K–Guided Strategy

Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation

ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease

American Heart Association/American College of Cardiology Foundation guide to warfarin therapy11The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.This statement has been co-published in the April 1, 2003, issue of Circulation.This statement was approved by the American Heart Association Science Advisory and Coordinating Committee in October 2002 and by the American College of Cardiology Board of Trustees in February 2003. A single reprint is available by calling 800-242-8721 (US only) or writing the American Heart Association, Public Information, 7272 Greenville Ave, Dallas, TX 75231-4596. Ask for reprint No. 71-0254. To purchase additional reprints: up to 999 copies, call 800-611-6083 (US only) or fax 413-665-2671; 1000 or more copies, call 410-528-4426, fax 410-528-4264, or e-mail klbradle@lww.com. To make photocopies for personal or educational use, call the Copyright Clearance Center, 978-750-8400.

Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update

Visceral Fat Accumulation and Its Relation to Plasma Hemostatic Factors in Healthy Men

Influence of Life Stress on Depression: Moderation by a Polymorphism in the 5-HTT Gene

Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and γ-glutamyl carboxylase) gene variants with warfarin sensitivity

2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation

Can Patients Be Anticoagulated After Intracerebral Hemorrhage?

Abdominal Visceral and Subcutaneous Adipose Tissue Compartments

Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics

Mechanism of Oxidation Reactions Catalyzed by Cytochrome P450 Enzymes

Photopharmacology: Beyond Proof of Principle

Venous thromboembolism in travellers

Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin

Serum insulin, haemostatic function and cardiovascular risk factors in normoglycaemic men and women

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

Dietary vitamin K influences intra‐individual variability in anticoagulant response to warfarin

Early discharge of patients with pulmonary embolism: a two-phase observational study

Traveller's thrombosis

Expression of chemokine receptors CXCR1 and CXCR2 during cardiopulmonary bypass

The role of strain gauge plethysmography in the assessment of patients with suspected deep vein thrombosis

A Randomized Trial of Genotype-Guided Dosing of Warfarin

The value of education and self‐monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation

Relation of Lipid Peroxides to Macrovascular Disease in Type 2 Diabetes

Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

Combination therapy of steroids and immunoglobulin in chronic refractory idiopathic thrombocytopenic purpura (ITP) enabling renal stone fragmentation by lithotripsy

Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism

Clinical risk factors for venous thrombosis associated with air travel.

Rescue thrombolysis: alteplase as adjuvant treatment after streptokinase in acute myocardial infarction.

A double-blind placebo controlled trial to study the efficacy and safety of a low molecular weight heparin fragment (fragmin) in patients having major elective general surgery

Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis

Warfarin dose requirement and CYP2C9 polymorphisms

Incidence of symptomatic thrombosis in a stable population of 650,000: travel and other risk factors.